|Bid||80.70 x 900|
|Ask||81.08 x 800|
|Day's Range||80.53 - 81.23|
|52 Week Range||80.53 - 98.52|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||18.64|
|Forward Dividend & Yield||3.20 (3.96%)|
|Ex-Dividend Date||Mar 04, 2021|
|1y Target Est||104.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NVSLearn more
Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades. Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.
Here's why they think Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS) are too cheap to ignore. Prosper Junior Bakiny (Bristol Myers Squibb): Investors are sometimes wary of undervalued companies.
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.